Luận án Tiến sĩ Y học: Nghiên cứu các đột biến TP53, BRAF trong mô ung thư da và mối liên quan của nó với các thể bệnh

9,841
170
140
65. Malumbres M., Barbacid M. (2003). RAS oncogenes: the first 30 years.
Nat. Rev. Cancer, 3, 459-465.
66. Kolch W. (2000). Meaningful ralationships: the regualtion of the Ras/
Raf/ MEK/ ERK pathway by protein interactions. Biochem. J, 351, 289-
305.
67. Morrison D.K (2001). KSR: a MAPK scaffold of the Ras pathway. J.
Cell Sci, 114, 1609-1612.
68. Zhang B.H, Guan K.L (2000). Activation of B-Raf kinase requires
phosphorylation of the conserved residues Thr589 and Ser601. EMBOJ,
19, 5429-5439.
69. Macdonal F., Ford C.R.J, Casson A.G (2005). Cyclins and cyclin -
dependent kinases. Molecular Biology of cancer, Bios scientific
publishers, London and Newyork, second edition, 64-68.
70. Davies H., Bignell G.R, Cox C. et al (2002). Mutations of the BRAF
gene in human cancer. Nature, 417, 949-954.
71. Cohen Y., Goldenberg C.N, Parrella P. et al (2003). Lack of BRAF
mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci, 44,
2876-2878.
72. Singer G., Oldt R., Cohen Y. et al (2003). Mutations in BRAF and
KRAS characterize the development of low - grade ovarian serous
carcinoma. J. Natl, Cancer Inst. 95, 484-486.
73. Brose M.S, Volpe P., Feldman M. et al (2002). BRAF and RAS
mutations in human lung cancer and melanoma. Cancer Res, 62, 6997-
7000.
74. Morrison D.K, Cutler R.E.J (1997). The complexity of Raf-1
Regulation. Curr. Opin. Cell Biol, 9, 174-179.
75. Rommel C., Clarke B.A, Zimmermann S. (1999). Differentiation stage-
specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286,
65. Malumbres M., Barbacid M. (2003). RAS oncogenes: the first 30 years. Nat. Rev. Cancer, 3, 459-465. 66. Kolch W. (2000). Meaningful ralationships: the regualtion of the Ras/ Raf/ MEK/ ERK pathway by protein interactions. Biochem. J, 351, 289- 305. 67. Morrison D.K (2001). KSR: a MAPK scaffold of the Ras pathway. J. Cell Sci, 114, 1609-1612. 68. Zhang B.H, Guan K.L (2000). Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr589 and Ser601. EMBOJ, 19, 5429-5439. 69. Macdonal F., Ford C.R.J, Casson A.G (2005). Cyclins and cyclin - dependent kinases. Molecular Biology of cancer, Bios scientific publishers, London and Newyork, second edition, 64-68. 70. Davies H., Bignell G.R, Cox C. et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-954. 71. Cohen Y., Goldenberg C.N, Parrella P. et al (2003). Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci, 44, 2876-2878. 72. Singer G., Oldt R., Cohen Y. et al (2003). Mutations in BRAF and KRAS characterize the development of low - grade ovarian serous carcinoma. J. Natl, Cancer Inst. 95, 484-486. 73. Brose M.S, Volpe P., Feldman M. et al (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 62, 6997- 7000. 74. Morrison D.K, Cutler R.E.J (1997). The complexity of Raf-1 Regulation. Curr. Opin. Cell Biol, 9, 174-179. 75. Rommel C., Clarke B.A, Zimmermann S. (1999). Differentiation stage- specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286,
1738-1741.
76. Campbell S.L, Khosravi F.R, Rossman K.L et al (1998). Increasing
complexity of Ras signaling. Der CJ Oncogene, Sep, 17, 1395-413.
77. Tsygankova O.M, Kupperman E., Wen W. et al (2000). Cyclic AMP
activates Ras. Oncogene, 19, 3609-3615.
78. Chandra S.P, Rafal S. et al (1011). Sequencing technologies and genome
sequencing. J. Appl Genet, 52(4), 413-435.
79. Rick K., Marinus J. B et al (2017). Next - Generation Sequencing in
Oncology: Genetic Diagnosis, Risk Prediction and Cancer
Classification. Int J MOl Sci, 18(2): 308-312.
80. John S., Editor (2018). Development of ultra-short PCR assay to reveal
BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS
One, 13(6): 200-208.
81. Đình Roanh (2003). Nghiên cứu ứng dụng Hóa miễn dịch
trong chẩn đoán một số bệnh ung thư. Đề tài cấp Bộ, Trường Đại học Y
Hà Nội.
82. Daum G., Eisenmann T.I, Fries H.W et al (1994). The ins and outs of
Raf kinases. Trends Biochem Sci, 19, 474-480.
83. Scrivener Y., Grosshans E., Cribier B. (2002). Viriations of basal cell
carcinomas accoding to gender, age, loacation and histopathological
subtype. Br. J. Dermatol, 147, 41-47.
84. Chang J.M, Gao X.M (2013). Clinical and histopathological
characteristics of basal cell carcinoma in Chinese patients. Chin. Med. J
(Engl), 126(2), 211-214.
85. Raasch B.A, Buettner P.G, Garbe C. (2006). Basal cell carcinoma:
histological classification and body - site distribution. Br. J. Dermatol,
155, 401-407.
86. Buettner P.G, Raasch B.A (1998). Incidence rates of skin cancer in
1738-1741. 76. Campbell S.L, Khosravi F.R, Rossman K.L et al (1998). Increasing complexity of Ras signaling. Der CJ Oncogene, Sep, 17, 1395-413. 77. Tsygankova O.M, Kupperman E., Wen W. et al (2000). Cyclic AMP activates Ras. Oncogene, 19, 3609-3615. 78. Chandra S.P, Rafal S. et al (1011). Sequencing technologies and genome sequencing. J. Appl Genet, 52(4), 413-435. 79. Rick K., Marinus J. B et al (2017). Next - Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J MOl Sci, 18(2): 308-312. 80. John S., Editor (2018). Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One, 13(6): 200-208. 81. Lê Đình Roanh (2003). Nghiên cứu ứng dụng Hóa mô miễn dịch trong chẩn đoán một số bệnh ung thư. Đề tài cấp Bộ, Trường Đại học Y Hà Nội. 82. Daum G., Eisenmann T.I, Fries H.W et al (1994). The ins and outs of Raf kinases. Trends Biochem Sci, 19, 474-480. 83. Scrivener Y., Grosshans E., Cribier B. (2002). Viriations of basal cell carcinomas accoding to gender, age, loacation and histopathological subtype. Br. J. Dermatol, 147, 41-47. 84. Chang J.M, Gao X.M (2013). Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients. Chin. Med. J (Engl), 126(2), 211-214. 85. Raasch B.A, Buettner P.G, Garbe C. (2006). Basal cell carcinoma: histological classification and body - site distribution. Br. J. Dermatol, 155, 401-407. 86. Buettner P.G, Raasch B.A (1998). Incidence rates of skin cancer in
Townsville, Australia. Int. J. Cancer, 78, 587-593.
87. Demers A.A, Nugent Z., Mihalcioiu C. et al (2005). Trends of
nonmelanoma skin cancer from 1960 through 2000 in a Canadian
population. J. Am. Dermatol, 53, 320-328.
88. Kikuchi A., Shimizu H., Nashikawa T. (1996). Basal cell carcinoma in
Japanese patients. Arch. Dermatol, 132(3), 320-324.
89. Hoey S.E, Devereux C.E, Murray L. et al (2007). Skin cancer trends in
Northern Ireland and consequences for provision of dermatology
services. Br. J. Dermatol, 156, 1301-1307.
90. Jurciukonyte R., Vincerzevskiene I., Krilaviciute A. et al (2013).
Epidemiology of basal cell carcinoma in Lithuania. 1996-2010. Br. J.
Dermatol, 169, 1100-1105.
91. Lomas A., Leonardi B.J, Bath H.F (2012). A systematic review of
worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol,
166, 1069-1080.
92. Lear J.T, Tan B.B, Smith A.G et al (1997). Risk factors for basal cell
carcinoma in the UK: case-control study in 806 patients. J. R. Soc. Med,
90(7), 371-374.
93. Pelucchi C., Landro A.D, Naldi L. et al (2007). Risk factors for
Histological Types and Anatomic Sites of Cutaneous Basal-Cell
Carcinoma: An Italian Case-Control Study. J. Invest. Dermatol, 127,
935-944.
94. Hoàng Anh Tuấn (2012). Nghiên cứu một số đặc điểm lâm sàng,
bệnh học và hóa mô miễn dịch ung thư biểu mô tế bào đáy và tuyến bã ở
mi mắt. Luận án tiến sỹ y học, Trường Đại học Y Hà Nội.
95. Malhotra P., Singh A., Ramesh V. (2011). Basal cell carcinoma in the
North Indian population: Clinicopathologic review and
immunohistochemical analysis. Indian J. Dermatol. Venereol. Leprol,
Townsville, Australia. Int. J. Cancer, 78, 587-593. 87. Demers A.A, Nugent Z., Mihalcioiu C. et al (2005). Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J. Am. Dermatol, 53, 320-328. 88. Kikuchi A., Shimizu H., Nashikawa T. (1996). Basal cell carcinoma in Japanese patients. Arch. Dermatol, 132(3), 320-324. 89. Hoey S.E, Devereux C.E, Murray L. et al (2007). Skin cancer trends in Northern Ireland and consequences for provision of dermatology services. Br. J. Dermatol, 156, 1301-1307. 90. Jurciukonyte R., Vincerzevskiene I., Krilaviciute A. et al (2013). Epidemiology of basal cell carcinoma in Lithuania. 1996-2010. Br. J. Dermatol, 169, 1100-1105. 91. Lomas A., Leonardi B.J, Bath H.F (2012). A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol, 166, 1069-1080. 92. Lear J.T, Tan B.B, Smith A.G et al (1997). Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J. R. Soc. Med, 90(7), 371-374. 93. Pelucchi C., Landro A.D, Naldi L. et al (2007). Risk factors for Histological Types and Anatomic Sites of Cutaneous Basal-Cell Carcinoma: An Italian Case-Control Study. J. Invest. Dermatol, 127, 935-944. 94. Hoàng Anh Tuấn (2012). Nghiên cứu một số đặc điểm lâm sàng, mô bệnh học và hóa mô miễn dịch ung thư biểu mô tế bào đáy và tuyến bã ở mi mắt. Luận án tiến sỹ y học, Trường Đại học Y Hà Nội. 95. Malhotra P., Singh A., Ramesh V. (2011). Basal cell carcinoma in the North Indian population: Clinicopathologic review and immunohistochemical analysis. Indian J. Dermatol. Venereol. Leprol,
77 (3), 328-330.
96. Hao Z.F, Ao J.H, Zhang J., Su Y.M, Yang R.Y (2013). ATF3 activates
Stat3 phosphorylation through inhibition of p53 expression in skin
cancer cells. Asian Pac. J. Cancer Prev, 14(12), 7439-7444.
97. Benjamin C.L, Ananthaswamy H.N (2007). p53 and the pathogenesis of
skin cancer. Toxicol. Appl. Pharmacol, 224, 241 - 48.
98. Ling G., Ahmadian A., Persson A. et al (2001). PATCHED and p53
gene alterations in sporadic and hereditary basal cell cancer. Oncogene,
20, 7770- 78.
99. Seidler A.M, Pennie M.L, Veledar E. et al (2010). Economic burden of
melanoma in the elderly population: population-based analysis of the
Surveillance. Epidemiology. and End Results (SEER)--Medicare data.
Arch Dermatol, 146(3), 249-256.
100. Zhang H., Ping X.L, Lee P.K et al (2001). Role of PTCH and p53 genes
in early-onset basal cell carcinoma. Am. J. Pathol,158, 381385.
101. Isobe M., Emanuel B.S, Givol D. et al (1986). Localization of gene for
human p53 tumour antigen to band 17p13. Nature, 320, 84-85.
102. Lane D.P (1992). Cancer. p53, guardian of the genome. Nature,
358(6381), 15-26.
103. Ling G., Ahmadian A., Persson A. et al (2001). PATCHED and p53
gene alterations in sporadic and hereditary basal cell cancer. Oncogene,
20, 7770- 78.
104. Rady P., Scinicariello F., Wagner R.F et al (1992). P53 mutations in
basal cell carcinomas. Cancer Res, 52, 3804 - 06.
105. Reifenberger J., Wolter M., Knobbe C.B et al (2005). Somatic mutations
in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell
carcinomas. Br. J. Dermatol,152, 4351.
106. Ziegler A., Jonason A.S, Leffell D.J et al (1994). Sunburn and p53 in the
77 (3), 328-330. 96. Hao Z.F, Ao J.H, Zhang J., Su Y.M, Yang R.Y (2013). ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells. Asian Pac. J. Cancer Prev, 14(12), 7439-7444. 97. Benjamin C.L, Ananthaswamy H.N (2007). p53 and the pathogenesis of skin cancer. Toxicol. Appl. Pharmacol, 224, 241 - 48. 98. Ling G., Ahmadian A., Persson A. et al (2001). PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene, 20, 7770- 78. 99. Seidler A.M, Pennie M.L, Veledar E. et al (2010). Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance. Epidemiology. and End Results (SEER)--Medicare data. Arch Dermatol, 146(3), 249-256. 100. Zhang H., Ping X.L, Lee P.K et al (2001). Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am. J. Pathol,158, 381–385. 101. Isobe M., Emanuel B.S, Givol D. et al (1986). Localization of gene for human p53 tumour antigen to band 17p13. Nature, 320, 84-85. 102. Lane D.P (1992). Cancer. p53, guardian of the genome. Nature, 358(6381), 15-26. 103. Ling G., Ahmadian A., Persson A. et al (2001). PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene, 20, 7770- 78. 104. Rady P., Scinicariello F., Wagner R.F et al (1992). P53 mutations in basal cell carcinomas. Cancer Res, 52, 3804 - 06. 105. Reifenberger J., Wolter M., Knobbe C.B et al (2005). Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol,152, 43–51. 106. Ziegler A., Jonason A.S, Leffell D.J et al (1994). Sunburn and p53 in the
onset of skin cancer. Nature, 372, 773-776.
107. Forbes S., Clements J., Dawson E. et al (2006). COSMIC 2005, Br J
Cancer, 94, 318-322.
108. Telmer C.A, An J., Malehorn D.E et al (2003). Detection and
assignment of TP53 mutations in tumor DNA using peptide mass
signature genotyping, Hum Mutat, 22, 158-165.
109. Viros A., Sanchez L.B, Pedersen M. et al (2014). Ultraviolet radiation
accelerates BRAF-driven melanomagenesis by targeting TP53. Nature,
511(7510), 478-482.
110. Thierry S. (2007). Handbook of p53 mutation in cell lines Version 1.0
07/2007. http://p53/free.fr p53@free.fr.
111. Rodrigues N.R, Rowan A., Smith M.E.F et al (1990). P53 mutations in
colorectal cancer Proc Natl Acad Sci USA, 87, 7555-59.
112. Weiss J., Schwechheimer K., Cavenee W.K et al (1993). Mutation and
expression of the p53 gene in malignant melanoma cell lines. Int J
Cancer, 54, 693-699.
113. Kastrinakis W.V, Ramchurren N., Rieger K.M et al (1995). Increased
incidence of p53 mutations is associated with hepatic metastasis in
colorectal neoplastic progression. Oncogene, 11, 647-652.
114. Rieger K.M, Little A.R, Swart J.M et al (1995). Human bladder
carcinoma cell lines as indicators of oncogenic change relevant to
urothelial neoplasticprogression. Br J Cancer ,72, 683-690.
115. Van G.M, Kaghad M., Leonard J.H et al (2000). Mutation analysis of
P73 and TP53 in Merkel cell carcinoma. Br J Cancer, 82, 823-826.
116. Mitsudomi T., Steinberg S.M, Nau M.M et al (1992). p53 Gene
Mutations in Non-Small-Cell Lung Cancer Cell Lines and Their
Correlation with the Presence of ras Mutations and Clinical Features.
Oncogene ,7, 171-180.
117. Guiseppina G.M, Alanin S. (2003). TP53 mutation in Human skin
onset of skin cancer. Nature, 372, 773-776. 107. Forbes S., Clements J., Dawson E. et al (2006). COSMIC 2005, Br J Cancer, 94, 318-322. 108. Telmer C.A, An J., Malehorn D.E et al (2003). Detection and assignment of TP53 mutations in tumor DNA using peptide mass signature genotyping, Hum Mutat, 22, 158-165. 109. Viros A., Sanchez L.B, Pedersen M. et al (2014). Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature, 511(7510), 478-482. 110. Thierry S. (2007). Handbook of p53 mutation in cell lines Version 1.0 07/2007. http://p53/free.fr p53@free.fr. 111. Rodrigues N.R, Rowan A., Smith M.E.F et al (1990). P53 mutations in colorectal cancer Proc Natl Acad Sci USA, 87, 7555-59. 112. Weiss J., Schwechheimer K., Cavenee W.K et al (1993). Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer, 54, 693-699. 113. Kastrinakis W.V, Ramchurren N., Rieger K.M et al (1995). Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene, 11, 647-652. 114. Rieger K.M, Little A.R, Swart J.M et al (1995). Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplasticprogression. Br J Cancer ,72, 683-690. 115. Van G.M, Kaghad M., Leonard J.H et al (2000). Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer, 82, 823-826. 116. Mitsudomi T., Steinberg S.M, Nau M.M et al (1992). p53 Gene Mutations in Non-Small-Cell Lung Cancer Cell Lines and Their Correlation with the Presence of ras Mutations and Clinical Features. Oncogene ,7, 171-180. 117. Guiseppina G.M, Alanin S. (2003). TP53 mutation in Human skin
cancers. Human mutation 21, 217 - 228.
118. Hahn H., Wicking C., Zaphiropoulous P.G et al (1996). Mutations of the
human homolog of Drosophila patched in the nevoid basal cell
carcinoma syndrome. Cell, 85, 841 - 851.
119. Zafeirious D.J, Fabrizio T., Alexander A. et al (2001). Xeroderma
Pigmentosum group G with severe neurological involvement and
features of cockayne syndrome in infancy. Pediatric research, 49, 407 -
412.
120. Dong Z., Zheng L., Liu W. (2015). Association of mRNA expression of
TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with
colorectal cancer risk in Asian population: a bioinformatics analysis and
meta-analysis. Cell, 85, 841 - 851.
121. Mastellaro M.J, Seidinge A.L, Kang G. et al (2015). Contribution of the
TP53 R337H mutation to the cancer burden in southern Brazil: insights
from the study of 55 families of children with adrenocortical tumors. Br
J Cancer, 76, 84 - 89.
122. Zampiga V., Danesi R., Tedadi G. et al (2016). Multiple primary tumors
in a family with Li-Flraumeni syndrome with a TP53 germline mutation
identified by next-generation sequencing. Cell, 15, 641 - 698.
123. Burns J.E, Baird M.C, Clark L.J et al (1993). Gene mutations and
increased levels of p53 protein in human squamous cell carcinomas and
their cell lines. Br J Cancer, 67, 1274-1284.
124. Ye X.H et al (2014). Association between the TP53 polymorphisms and
lun cancerrisk a meta-analysis. Mol Biol Rep, 41(1), 373-85
125. Venza M., Catalano T., Visalli M. et al (2009). Association of the DSS1
c.143G>A polymorphism with skin squamous cell carcinoma. J Cutan
Pathol, 36(2), 220-8.
126. Bukhari M.H, Niazi S., Khaleel M.E et al (2011), Elevated frequency of
p53 genetic mutations and AgNOR values in squamous cell carcinoma.
cancers. Human mutation 21, 217 - 228. 118. Hahn H., Wicking C., Zaphiropoulous P.G et al (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell, 85, 841 - 851. 119. Zafeirious D.J, Fabrizio T., Alexander A. et al (2001). Xeroderma Pigmentosum group G with severe neurological involvement and features of cockayne syndrome in infancy. Pediatric research, 49, 407 - 412. 120. Dong Z., Zheng L., Liu W. (2015). Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis. Cell, 85, 841 - 851. 121. Mastellaro M.J, Seidinge A.L, Kang G. et al (2015). Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: insights from the study of 55 families of children with adrenocortical tumors. Br J Cancer, 76, 84 - 89. 122. Zampiga V., Danesi R., Tedadi G. et al (2016). Multiple primary tumors in a family with Li-Flraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. Cell, 15, 641 - 698. 123. Burns J.E, Baird M.C, Clark L.J et al (1993). Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer, 67, 1274-1284. 124. Ye X.H et al (2014). Association between the TP53 polymorphisms and lun cancerrisk a meta-analysis. Mol Biol Rep, 41(1), 373-85 125. Venza M., Catalano T., Visalli M. et al (2009). Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. J Cutan Pathol, 36(2), 220-8. 126. Bukhari M.H, Niazi S., Khaleel M.E et al (2011), Elevated frequency of p53 genetic mutations and AgNOR values in squamous cell carcinoma.
Carcinogenesis, 32(3),327-30.
127. Almquist L.M, Karagas M.R, Christensen B.C et al (2010). The role of
TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-
melanoma skin cancer. J Invest Dermatol, 130(6), 1719-25.
128. Aggarwal M., Saxena R., Sinclaier E. et al (1016). Reactivation of
mutant p53 by dietary-related compound phenethyl isothiocyanate
inhibits tumor growth. Cell Death Differ, 23, 10, 1615-27.
129. Zhang M., Heldin A., Paloma S.M et al (2018) Synergistic rescue of
nosense mutant tomor suppressor p53 by combination treatmant with
aminoglycosides and Mdm2. Front Oncol, 4, 323-327.
130. Fujjita Y., Kato I., Iwai S. et al (2009). Role of p53 mutation in the
effect of boron neutron capture therrapy on oral squamaus cell
caecinoma. Radiat Oncol, 11, 54-63.
131. Zhao D., Tahaney W.M, Mazumdar A. et al (2017). Molecularly
targeted therapies for p53-mutant cancers. Cell Mol Life Sci,
74(22):4171-4187.
132. Tang X., Zhu Y., Han L. et al (2007). CP-31398 restores mutant p53
tumor suppressor function and inhibits UVB-induced skin
carcinogenesis in mine. J Clin Invest, 117(12), 3753-64.
133. He X., Kong X., Yan J. (2015). CP-31398 prevents the growth of p53-
mutated colorectal cancer cells in vitro and in vivo. Tumour Biol. 36(3),
437-441.
134. Hugdahl E., Kalvenes M .B, Puntervoll H.E et al (2016). BRAF V600E
expression in primary nodular melanoma is associated with aggressive
tumour features and reducced survival. Br J Cancer. 114(7): 801-8.
135. Brose M.S, Volpe P., Feldman M. et al (2002). BRAF and RAS
mutations in human lung cancer and melanoma. Cancer Res, 62, 6997-
7000
136. Si L., Kong Y., Xu X. et al (2012). Prevalence of BRAF V600E
Carcinogenesis, 32(3),327-30. 127. Almquist L.M, Karagas M.R, Christensen B.C et al (2010). The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non- melanoma skin cancer. J Invest Dermatol, 130(6), 1719-25. 128. Aggarwal M., Saxena R., Sinclaier E. et al (1016). Reactivation of mutant p53 by dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ, 23, 10, 1615-27. 129. Zhang M., Heldin A., Paloma S.M et al (2018) Synergistic rescue of nosense mutant tomor suppressor p53 by combination treatmant with aminoglycosides and Mdm2. Front Oncol, 4, 323-327. 130. Fujjita Y., Kato I., Iwai S. et al (2009). Role of p53 mutation in the effect of boron neutron capture therrapy on oral squamaus cell caecinoma. Radiat Oncol, 11, 54-63. 131. Zhao D., Tahaney W.M, Mazumdar A. et al (2017). Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci, 74(22):4171-4187. 132. Tang X., Zhu Y., Han L. et al (2007). CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mine. J Clin Invest, 117(12), 3753-64. 133. He X., Kong X., Yan J. (2015). CP-31398 prevents the growth of p53- mutated colorectal cancer cells in vitro and in vivo. Tumour Biol. 36(3), 437-441. 134. Hugdahl E., Kalvenes M .B, Puntervoll H.E et al (2016). BRAF –V600E expression in primary nodular melanoma is associated with aggressive tumour features and reducced survival. Br J Cancer. 114(7): 801-8. 135. Brose M.S, Volpe P., Feldman M. et al (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 62, 6997- 7000 136. Si L., Kong Y., Xu X. et al (2012). Prevalence of BRAF V600E
mutation in Chinese menanoma in a patients: large scale analysis of
BRAF and NRAS mutation in a 432 case cohort. Eur J cancer, 48(1):
94-100.
137. Sheen Y.S, Liao Y.H, Liau J.Y et al (2016). Prevalence of BRAF and
NRAS mutation in cutaneous melanoma patients in Taiwan. J Formos
Med Assoc, 115 (2): 121-127.
138. Thomas N.E, Edmistson S.N, Kanetsky P.A et al (2017). Association of
MC1R genotype and patient phenotypes with BRAF and NRAS
mutations in Melonoma. J Invest Dermatol, 137 (12): 2588-98.
139. Cohen Y., Goldenberg C.N, Parrella P. et al (2003), Lack of BRAF
mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci, 44:
2876-2878.
140. Bhavana P., April K. (2016). Updates in therapy for advanced
melanoma. Cancers Review, 8(17):103390.
141. Tarhini A. (2013). Immune-mediated adverse events associated with
ipilimumab ctla-4 blockade therapy: the underlying mechanisms and
clinical management. Scientifica, 2013:857519.
142. Robert C. et al (2015). Pembrolizumab versus Ipilimumab in Advanced
Melanoma. The New England journal of medicine, 372(26):2521-32.
143. Guo X., Fujino Y., Ye X. et al (2006). Association between multi-level
inorganic arsenic exposure from drinking water and skin lesions in
China. Int J Environ Res Public Health, 3 (3): 262-267.
144. Karagas M.R, Nelson H.H, Sehr P. et al (2006). Human papilloma virus
infection and incidence of squamous cell and basal cell carcinoma of the
skin. J. Nalt. Cancer Inst, 98 (6):389-395.
145. Gallagher R.P, Bajdik C.D, Fincham S. et al (1996). Chemical
exposures, medical history, and risk of squamous and basal cell
carcinoma of the skin. Cancer Epidemiol Biomarkers Prev, 5 (6): 419-
424.
mutation in Chinese menanoma in a patients: large scale analysis of BRAF and NRAS mutation in a 432 case cohort. Eur J cancer, 48(1): 94-100. 137. Sheen Y.S, Liao Y.H, Liau J.Y et al (2016). Prevalence of BRAF and NRAS mutation in cutaneous melanoma patients in Taiwan. J Formos Med Assoc, 115 (2): 121-127. 138. Thomas N.E, Edmistson S.N, Kanetsky P.A et al (2017). Association of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in Melonoma. J Invest Dermatol, 137 (12): 2588-98. 139. Cohen Y., Goldenberg C.N, Parrella P. et al (2003), Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci, 44: 2876-2878. 140. Bhavana P., April K. (2016). Updates in therapy for advanced melanoma. Cancers Review, 8(17):103390. 141. Tarhini A. (2013). Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica, 2013:857519. 142. Robert C. et al (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine, 372(26):2521-32. 143. Guo X., Fujino Y., Ye X. et al (2006). Association between multi-level inorganic arsenic exposure from drinking water and skin lesions in China. Int J Environ Res Public Health, 3 (3): 262-267. 144. Karagas M.R, Nelson H.H, Sehr P. et al (2006). Human papilloma virus infection and incidence of squamous cell and basal cell carcinoma of the skin. J. Nalt. Cancer Inst, 98 (6):389-395. 145. Gallagher R.P, Bajdik C.D, Fincham S. et al (1996). Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev, 5 (6): 419- 424.
PHỤ LỤC
PHỤ LỤC
PHỤ LỤC 1: DANH MỤC CHỮ VIẾT TẮT CÁC ACID AMIN
STT
Tên acid amin
Tên viết tắt
Ký hiệu
1.
Alanine
Ala
A
2.
Arginine
Arg
R
3.
Asparagine
Asn
B
4.
Aspartate
Asp
D
5.
Cysteine
Cys
C
6.
Glutaminte
Glu
E
7.
Glutamine
Gln
Q
8.
Glycine
Gly
G
9.
Histidine
His
H
10.
Isolcucine
Ile
I
11.
Leucine
Leu
L
12.
Lysine
Lys
K
13.
Methionine
Met
M
14.
Phenylalanin
Phe
F
15.
Proline
Pro
P
16.
Serine
Ser
S
17.
Threonine
Thr
T
18.
Tryptophan
Trp
W
19.
Tyrosine
Tyr
Y
20.
Valine
Val
V
PHỤ LỤC 1: DANH MỤC CHỮ VIẾT TẮT CÁC ACID AMIN STT Tên acid amin Tên viết tắt Ký hiệu 1. Alanine Ala A 2. Arginine Arg R 3. Asparagine Asn B 4. Aspartate Asp D 5. Cysteine Cys C 6. Glutaminte Glu E 7. Glutamine Gln Q 8. Glycine Gly G 9. Histidine His H 10. Isolcucine Ile I 11. Leucine Leu L 12. Lysine Lys K 13. Methionine Met M 14. Phenylalanin Phe F 15. Proline Pro P 16. Serine Ser S 17. Threonine Thr T 18. Tryptophan Trp W 19. Tyrosine Tyr Y 20. Valine Val V